Literature DB >> 19362982

Novel therapeutic agents in Waldenström's macroglobulinemia.

Irene M Ghobrial1, Xavier Leleu, Abdel Kareem Azab, Judith Runnels, Xiaoying Jia, Hai Ngo, Molly Melhem, Feda Azab, Antonio Sacco, Phong Quang, Nicholas Burwick, Anne-Sophie Moreau, Emanuel Husu, Mena Farag, Aldo Roccaro.   

Abstract

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19362982      PMCID： PMC3133646          DOI： 10.3816/CLM.2009.n.022

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN： 1557-9190


  10 in total

1.  Defining Waldenstrom's macroglobulinemia.

Authors:  Steven P Treon; Meletios Dimopoulos; Robert A Kyle
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Diagnosis and management of Waldenstrom's macroglobulinemia.

Authors:  Meletios A Dimopoulos; Robert A Kyle; Athanasios Anagnostopoulos; Steven P Treon
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

3.  Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

Authors:  Steven P Treon; Morie A Gertz; Meletios Dimopoulos; Athanasios Anagnostopoulos; Joan Blade; Andrew R Branagan; Ramon Garcia-Sanz; Stephen Johnson; Eva Kimby; Veronique Leblond; Jean-Paul Fermand; David G Maloney; Giampaolo Merlini; Pierre Morel; Enrica Morra; Gwen Nichols; Enrique M Ocio; Roger Owen; Marvin J Stone
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 5.  Waldenström macroglobulinemia.

Authors:  Arun Vijay; Morie A Gertz
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

6.  The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Xiaoying Jia; Judith Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben Carrasco; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

7.  Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

Authors:  Anne-Sophie Moreau; Xiaoying Jia; Hai T Ngo; Xavier Leleu; Garrett O'Sullivan; Yazan Alsayed; Alexey Leontovich; Klaus Podar; Jeffrey Kutok; John Daley; Suzan Lazo-Kallanian; Evdoxia Hatjiharissi; Marc S Raab; Lian Xu; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

8.  Targeting NF-kappaB in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Jérôme Eeckhoute; Xiaoying Jia; Aldo M Roccaro; Anne-Sophie Moreau; Mena Farag; Antonio Sacco; Hai T Ngo; Judith Runnels; Molly R Melhem; Nicolas Burwick; Abdelkareem Azab; Feda Azab; Zachary Hunter; Evdoxia Hatjiharissi; Daniel R Carrasco; Steven P Treon; Thomas E Witzig; Teru Hideshima; Myles Brown; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

Review 9.  Waldenström macroglobulinaemia.

Authors:  Irene M Ghobrial; Morie A Gertz; Rafael Fonseca
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

10.  Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Xavier Leleu; Antonio Sacco; Xiaoying Jia; Molly Melhem; Anne-Sophie Moreau; Hai T Ngo; Judith Runnels; Abdelkareem Azab; Feda Azab; Nicholas Burwick; Mena Farag; Steven P Treon; Michael A Palladino; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-03-03       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.